{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"BMRA","limit":50},"count":50,"signals":[{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":24,"context":"Notice includes the names of the nominees to be our Board of Directors (the Board) for election; | | |  |  |  | | |  |  2. |  To approve, on a non-binding advisory basis, the compensation paid to our named executive officers as disclosed in this proxy statement; | | |  |  |  | | |  |  3. |  To ratify the selection of Haskell & White LLP as our independent registered public accounting firm for our fiscal year ending May","filed_date":"2025-10-20","accession":"0001493152-25-018668","full_text":"https://origin.rootz.global/static/filing/0001493152-25-018668.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":14,"context":"paid to executive officers that is granted, earned, or vested based wholly or in part upon attainment of a financial reporting measure. **ITEM 11. EXECUTIVE COMPENSATION** **EXECUTIVE COMPENSATION OF NAMED EXECUTIVE OFFICERS** In December 2024, our Compensation Committee conducted its annual review of our compensation philosophy and made recommendations to the Board, which set the total compensation plan for our Named E","filed_date":"2025-09-26","accession":"0001493152-25-015785","full_text":"https://origin.rootz.global/static/filing/0001493152-25-015785.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":42,"context":"ether to invest in our securities. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on our business, reputation, revenue, financial condition, results of operations, and future prospects, in which event the market price of our Common Stock could decline, and you could lose part or a","filed_date":"2025-08-29","accession":"0001641172-25-026041","full_text":"https://origin.rootz.global/static/filing/0001641172-25-026041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":23,"context":"otice includes the names of the nominees to be presented by the Board of Directors for election; | | |  |  |  | | |  |  2. |  To approve, on a non-binding advisory basis, the compensation paid to our named executive officers as disclosed in this proxy statement; | | |  |  |  | | |  |  3. |  To ratify the selection of Haskell & White LLP as our independent registered public accounting firm for our fiscal year ending May","filed_date":"2024-09-30","accession":"0001493152-24-038820","full_text":"https://origin.rootz.global/static/filing/0001493152-24-038820.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":40,"context":"r technology, product, and market development efforts are unsuccessful or delayed. Furthermore, our failure to successfully introduce new technologies or products and develop new markets could have a material adverse effect on our business and prospects. **The Company is required to obtain government or regulatory certification in many countries and the European community to sell its products in those countries or regio","filed_date":"2024-08-28","accession":"0001493152-24-034208","full_text":"https://origin.rootz.global/static/filing/0001493152-24-034208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":32,"context":"d in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders equity or results of operations of the Company and the Subsidiaries taken as a w","filed_date":"2024-05-10","accession":"0001493152-24-018697","full_text":"https://origin.rootz.global/static/filing/0001493152-24-018697.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":23,"context":"otice includes the names of the nominees to be presented by the Board of Directors for election; | | |  |  |  | | |  |  2. |  To approve, on a non-binding advisory basis, the compensation paid to our Named Executive Officers as disclosed in this Proxy Statement; | | |  |  |  | | |  |  3. |  To ratify the selection by the Audit Committee of our Board of Directors of Haskell & White LLP as our independent public accountin","filed_date":"2023-09-27","accession":"0001493152-23-034447","full_text":"https://origin.rootz.global/static/filing/0001493152-23-034447.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":25,"context":"economic calamities. The pandemic, war, and geopolitical related disruptions have materially negatively impacted the Companys operations and financial performance and may continue to have significant material negative impacts on the Company depending on possible disruptions from future outbreaks or issues. Our net sales were approximately $5,339,000 for fiscal 2023 compared to $18,871,000 for fiscal 2022. For the fiscal","filed_date":"2023-08-25","accession":"0001493152-23-030254","full_text":"https://origin.rootz.global/static/filing/0001493152-23-030254.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":23,"context":"ies this Notice includes the names of the nominees to be presented by the Board of Directors for election; | | | | | | | 2. | To approve, on a non-binding advisory basis, the compensation paid to our Named Executive Officers as disclosed in this Proxy Statement; | | | | | | | 3. | To approve, on a non-binding advisory basis, the frequency of future advisory votes on the compensation paid to our Named Executive Officers;","filed_date":"2022-09-27","accession":"0001513162-22-000119","full_text":"https://origin.rootz.global/static/filing/0001513162-22-000119.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":25,"context":"credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact our operations and financial performance and may continue to have significant material negative impacts on us.  Our net sales were approximately $18,871,000 for fiscal 2022 compared to $7,199,000 for fiscal 2021. For the fiscal years ended May 31, 2022 and 2021, the Company had two distributors, which","filed_date":"2022-08-29","accession":"0001513162-22-000114","full_text":"https://origin.rootz.global/static/filing/0001513162-22-000114.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":22,"context":"t which accompanies this Notice includes the names of the nominees to be presented by the Board of Directors for election; 2. To approve, on a non-binding advisory basis, the compensation paid to our named executive officers as disclosed in this proxy statement; 3. To approve, on a non-binding advisory basis, the frequency of future advisory votes on the compensation paid to our named executive officers; 4. To ratify th","filed_date":"2021-09-28","accession":"0001513162-21-000114","full_text":"https://origin.rootz.global/static/filing/0001513162-21-000114.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":23,"context":"credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact our operations and financial performance and may continue to have significant material negative impacts on us.  For the fiscal years ended May 31, 2021 and 2020, the Company had two distributors and three distributors, respectively, which accounted for a total of 60% and 57% of our net consolidated sa","filed_date":"2021-08-27","accession":"0001513162-21-000112","full_text":"https://origin.rootz.global/static/filing/0001513162-21-000112.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":22,"context":"nt which accompanies this Notice includes the names of the nominees to be presented by the Board of Directors for election; 2. To approve on a non-binding advisory basis, the compensation paid to our named executive officers as disclosed in this proxy statement; 3. To approve, on a non-binding advisory basis the frequency of future advisory votes on the compensation paid to our named executive officers; 4. To consider a","filed_date":"2020-09-25","accession":"0001513162-20-000207","full_text":"https://origin.rootz.global/static/filing/0001513162-20-000207.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":22,"context":"redit risk, and general economic calamities. These pandemic related disruptions can materially negatively impact the Companys operations and financial performance and may continue to have significant material negative impacts on the Company.  5 On March 17, 2020, the Company announced it had commenced shipping initial samples of its COVID-19 IgG/IgM Rapid Test (qualitative membrane-based immunoassay for the detection of","filed_date":"2020-08-31","accession":"0001513162-20-000185","full_text":"https://origin.rootz.global/static/filing/0001513162-20-000185.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":19,"context":"mental laws. Any environmental or safety violation or remediation requirement could also partially or completely shut down our research and manufacturing facilities and operations, which would have a material adverse effect on our business. The risk of accidental contamination or injury from these hazardous materials cannot be completely eliminated and exposure of individuals to these materials could result in substanti","filed_date":"2019-08-29","accession":"0001513162-19-000194","full_text":"https://origin.rootz.global/static/filing/0001513162-19-000194.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":20,"context":"th environmental laws. Any environmental violation or remediation requirement could also partially or completely shut down our research and manufacturing facilities and operations, which would have a material adverse effect on our business. The risk of accidental contamination or injury from these hazardous materials cannot be completely eliminated and exposure of individuals to these materials could result in substanti","filed_date":"2018-08-29","accession":"0001513162-18-000223","full_text":"https://origin.rootz.global/static/filing/0001513162-18-000223.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":40,"context":"ement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, be reasonably expected to have a material adverse effect on the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders equity or results of operations of the Company and the Subsidiaries taken as a w","filed_date":"2017-12-04","accession":"0001513162-17-000319","full_text":"https://origin.rootz.global/static/filing/0001513162-17-000319.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":20,"context":"th environmental laws. Any environmental violation or remediation requirement could also partially or completely shut down our research and manufacturing facilities and operations, which would have a material adverse effect on our business. The risk of accidental contamination or injury from these hazardous materials cannot be completely eliminated and exposure of individuals to these materials could result in substanti","filed_date":"2017-08-29","accession":"0001513162-17-000246","full_text":"https://origin.rootz.global/static/filing/0001513162-17-000246.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":28,"context":"y such person during the period commencing on the Closing Date and ending on the date that is one hundred eighty (180) days following the Closing Date, in the form of **Exhibit B** attached hereto. **Material Adverse Effect** shall have the meaning assigned to such term in Section 3.1(b). **Material Permits** shall have the meaning ascribed to such term in Section 3.1(n). **Money Laundering Laws** shall have the meaning","filed_date":"2026-08-26","accession":"0001493152-26-040251","full_text":"https://origin.rootz.global/static/filing/0001493152-26-040251.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":43,"context":"ether to invest in our securities. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on our business, reputation, revenue, financial condition, results of operations, and future prospects, in which event the market price of our Common Stock could decline, and you could lose part or a","filed_date":"2026-08-31","accession":"0001493152-26-040851","full_text":"https://origin.rootz.global/static/filing/0001493152-26-040851.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":80,"match_count":10,"context":"moval. The Proxy Statement which accompanies this Notice includes the names of the nominees to be presented by the Board of Directors for election; and 2. To approve on an advisory, non-binding basis named executive officer compensation as disclosed in this proxy statement; 3. To ratify the selection by the Audit Committee of the Company's Board of Directors of PKF, Certified Public Accountants, a Professional Corporati","filed_date":"2016-09-28","accession":"0001513162-16-001015","full_text":"https://origin.rootz.global/static/filing/0001513162-16-001015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":60,"match_count":5,"context":"ols and procedures, equipment malfunction, environmental factors or damage to one or more of our facilities could adversely affect our ability to manufacture our products. This, in turn, could have a material adverse effect on our business. If we experience unexpected increases in the demand for our products, we may be required to expend additional capital resources to meet these demands. These capital resources could i","filed_date":"2019-06-05","accession":"0001513162-19-000146","full_text":"https://origin.rootz.global/static/filing/0001513162-19-000146.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_concentration","strength":58,"match_count":1,"context":"nded May 31, 2020, one vendor accounted for 59.3% of the purchases of raw materials. For the year ended May 31, 2019, two vendors accounted for a total of 23.8 % of the purchases of raw materials.  **GEOGRAPHIC CONCENTRATION** As of May 31, 2020 and 2019, approximately $613,000 and $665,000 of Biomerica's gross inventory and approximately $31,000 and $39,000, of Biomerica's property and equipment, net of accumulated depr","filed_date":"2020-08-31","accession":"0001513162-20-000185","full_text":"https://origin.rootz.global/static/filing/0001513162-20-000185.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"platform_shift","strength":56,"match_count":7,"context":"rable size, but have had limited marketing capability. We are working on expanding this capability through marketing and strategic cooperation with larger companies and distributors as well as hiring new marketing and sales expertise.  **GOVERNMENT REGULATION OF OUR DIAGNOSTIC BUSINESS** Our primary business consists of selling products that are legally defined to be in vitro diagnostic and medical devices.","filed_date":"2019-08-29","accession":"0001513162-19-000194","full_text":"https://origin.rootz.global/static/filing/0001513162-19-000194.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":55,"match_count":5,"context":"t liability. An inability to obtain sufficient insurance coverage could prevent or inhibit the commercialization of Biomerica's products. In addition, a product liability claim or recall could have a material adverse effect on the business or financial condition of the Company. Hazardous Materials - Biomerica's manufacturing and research and development involves the controlled use of hazardous materials and chemicals. A","filed_date":"2016-08-29","accession":"0001513162-16-000987","full_text":"https://origin.rootz.global/static/filing/0001513162-16-000987.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":55,"match_count":5,"context":"t liability. An inability to obtain sufficient insurance coverage could prevent or inhibit the commercialization of Biomerica's products. In addition, a product liability claim or recall could have a material adverse effect on the business or financial condition of the Company. Hazardous Materials - Biomerica's manufacturing and research and development involves the controlled use of hazardous materials and chemicals. A","filed_date":"2015-08-31","accession":"0001513162-15-000518","full_text":"https://origin.rootz.global/static/filing/0001513162-15-000518.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":55,"match_count":5,"context":"t liability. An inability to obtain sufficient insurance coverage could prevent or inhibit the commercialization of Biomerica's products. In addition, a product liability claim or recall could have a material adverse effect on the business or financial condition of the Company. Hazardous Materials - Biomerica's manufacturing and research and development involves the controlled use of hazardous materials and chemicals. A","filed_date":"2014-08-29","accession":"0001513162-14-000506","full_text":"https://origin.rootz.global/static/filing/0001513162-14-000506.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":55,"match_count":5,"context":"t liability. An inability to obtain sufficient insurance coverage could prevent or inhibit the commercialization of Biomerica's products. In addition, a product liability claim or recall could have a material adverse effect on the business or financial condition of the Company. Hazardous Materials - Biomerica's manufacturing and research and development involves the controlled use of hazardous materials and chemicals. A","filed_date":"2013-08-29","accession":"0001513162-13-000655","full_text":"https://origin.rootz.global/static/filing/0001513162-13-000655.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":55,"match_count":5,"context":"t liability. An inability to obtain sufficient insurance coverage could prevent or inhibit the commercialization of Biomerica's products. In addition, a product liability claim or recall could have a material adverse effect on the business or financial condition of the Company. Hazardous Materials - Biomerica's manufacturing and research and development involves the controlled use of hazardous materials and chemicals. A","filed_date":"2012-08-29","accession":"0001513162-12-000654","full_text":"https://origin.rootz.global/static/filing/0001513162-12-000654.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_concentration","strength":53,"match_count":1,"context":"f vendor spend for raw materials. For the fiscal year ended May 31, 2022, the Company had one vendor, which accounted for 84% of our purchases of raw materials largely related to COVID-19 products. **GEOGRAPHIC CONCENTRATION** As of May 31, 2023 and 2022, approximately $626,000 and $621,000, respectively, of Biomericas gross inventory was located in Mexicali, Mexico, respectively. As of May 31, 2023 and 2022, approximate","filed_date":"2023-08-25","accession":"0001493152-23-030254","full_text":"https://origin.rootz.global/static/filing/0001493152-23-030254.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":50,"match_count":5,"context":"material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on our consolidated financial position, results of operations or cash flows. There were no legal proceedings pending as of August 31, 2025. **NOTE 7: SUBSEQUENT EVENTS** None. | 13 | | **ITEM 2. MANA","filed_date":"2025-10-14","accession":"0001493152-25-018043","full_text":"https://origin.rootz.global/static/filing/0001493152-25-018043.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_concentration","strength":49,"match_count":3,"context":"ernational distributors, as well as hospitals, clinical laboratories, medical research institutions, pharmaceutical companies, drugstores, wholesalers, physicians offices, and e-commerce customers. A significant portion of our revenues are derived from international sales. We employ a Director of International Sales, based in Germany, who has over 25 years of experience in diagnostics and life sciences. This individuals internatio","filed_date":"2026-08-31","accession":"0001493152-26-040851","full_text":"https://origin.rootz.global/static/filing/0001493152-26-040851.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"platform_shift","strength":48,"match_count":6,"context":"in, and protect our technology, our operating results could be adversely affected. **To remain competitive, we must expend considerable resources to research new technologies and products and develop new markets, and there is no assurance our efforts to develop new technologies, products, or markets will be successful or such technologies, products, or markets will be commercially viable.** We devote a sign","filed_date":"2025-08-29","accession":"0001641172-25-026041","full_text":"https://origin.rootz.global/static/filing/0001641172-25-026041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"platform_shift","strength":48,"match_count":6,"context":"in, and protect our technology, our operating results could be adversely affected. **To remain competitive, we must expend considerable resources to research new technologies and products and develop new markets, and there is no assurance our efforts to develop new technologies, products, or markets will be successful or such technologies, products, or markets will be commercially viable.** **** We devote a","filed_date":"2024-08-28","accession":"0001493152-24-034208","full_text":"https://origin.rootz.global/static/filing/0001493152-24-034208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"platform_shift","strength":48,"match_count":6,"context":"f products, but have had limited marketing capability. We are working on expanding this capability through marketing and strategic cooperation with larger companies and distributors as well as hiring new marketing and sales expertise.  **GOVERNMENT REGULATION OF OUR DIAGNOSTIC BUSINESS** Our primary business consists of selling products that are generally legally defined to be in vitro diagnostic and medica","filed_date":"2020-08-31","accession":"0001513162-20-000185","full_text":"https://origin.rootz.global/static/filing/0001513162-20-000185.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"platform_shift","strength":48,"match_count":6,"context":"ubstantial fines, penalties or damages that are not covered by insurance. **In order to remain competitive, we must expend considerable resources to research new technologies and products and develop new markets, and there is no assurance our efforts to develop new technologies, products or markets will be successful or such technologies, products or markets will be commercially viable.** We devote a signif","filed_date":"2018-08-29","accession":"0001513162-18-000223","full_text":"https://origin.rootz.global/static/filing/0001513162-18-000223.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":48,"match_count":6,"context":"ctors shall be elected by a plurality of the votes cast at the meeting of stockholders. The affirmative vote of a majority of the votes properly cast is required to approve, on an advisory basis, the Named Executive Officers Compensation and to ratify the selection of PKF, LLP as the Company's independent public accounting firm for the current fiscal year. Abstentions on such election and the other proposal, and any bro","filed_date":"2017-09-28","accession":"0001513162-17-000270","full_text":"https://origin.rootz.global/static/filing/0001513162-17-000270.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"platform_shift","strength":48,"match_count":6,"context":"substantial fines, penalties or damages that are not covered by insurance. In order to remain competitive, we must expend considerable resources to research new technologies and products and develop new markets, and there is no assurance our efforts to develop new technologies, products or markets will be successful or such technologies, products or markets will be commercially viable. We devote a signific","filed_date":"2017-08-29","accession":"0001513162-17-000246","full_text":"https://origin.rootz.global/static/filing/0001513162-17-000246.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"platform_shift","strength":48,"match_count":6,"context":"d intellectual property rights, our operating results could be adversely affected. **To remain competitive, we must expend considerable resources to research new technologies and products and develop new markets, and there is no assurance our efforts to develop new technologies, products, or markets will be successful or such technologies, products, or markets will be commercially viable.** We devote a sign","filed_date":"2026-08-31","accession":"0001493152-26-040851","full_text":"https://origin.rootz.global/static/filing/0001493152-26-040851.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_concentration","strength":46,"match_count":2,"context":"nd results of operations. We also have supply agreements with foreign vendors that involve sharing foreign currency exchange fluctuation risks. We may enter into similar arrangements in the future. A significant portion of our revenues comes from sales to our distribution partner in China. Political tensions between the U.S. and China could disrupt or reduce our sales in the Chinese market, posing a substantial risk to our busines","filed_date":"2024-08-28","accession":"0001493152-24-034208","full_text":"https://origin.rootz.global/static/filing/0001493152-24-034208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_concentration","strength":43,"match_count":1,"context":"year ended May 31, 2021, one vendor accounted for 58% of the purchases of raw materials. For the year ended May 31, 2020, one vendor accounted for a total of 59% of the purchases of raw materials.  **GEOGRAPHIC CONCENTRATION** As of May 31, 2021 and 2020, approximately $803,000 and $613,000 of Biomerica's gross inventory and approximately $25,000 and $31,000, of Biomerica's property and equipment, net of accumulated depr","filed_date":"2021-08-27","accession":"0001513162-21-000112","full_text":"https://origin.rootz.global/static/filing/0001513162-21-000112.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_concentration","strength":43,"match_count":1,"context":"8, two vendors accounted for 27.7 % of the purchases of raw materials. As of May 31, 2019 and 2018 the Company had one vendor which accounted for 32.1% and 29.1%, respectively, of accounts payable. **GEOGRAPHIC CONCENTRATION** As of May 31, 2019 and 2018, approximately $665,000 and $657,000 of Biomerica's gross inventory and approximately $39,000 and $41,000, of Biomerica's property and equipment, net of accumulated depr","filed_date":"2019-08-29","accession":"0001513162-19-000194","full_text":"https://origin.rootz.global/static/filing/0001513162-19-000194.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":42,"match_count":4,"context":"material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on our consolidated financial position, results of operations or cash flows. There were no material legal proceedings pending as of November 30, 2025. **NOTE 7: SUBSEQUENT EVENTS** None. | 12 | | **I","filed_date":"2026-01-14","accession":"0001493152-26-002286","full_text":"https://origin.rootz.global/static/filing/0001493152-26-002286.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":42,"match_count":4,"context":"material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Companys consolidated financial position, results of operations or cash flows. There were no material legal proceedings pending as of February 28, 2025. **NOTE 7: SUBSEQUENT EVENTS** None. | 1","filed_date":"2025-04-14","accession":"0001641172-25-004571","full_text":"https://origin.rootz.global/static/filing/0001641172-25-004571.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":42,"match_count":4,"context":"material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Companys consolidated financial position, results of operations or cash flows. There were no material legal proceedings pending as of November 30, 2024. | 12 | | **ITEM 2. MANAGEMENTS DISCUSSI","filed_date":"2025-01-14","accession":"0001493152-25-002209","full_text":"https://origin.rootz.global/static/filing/0001493152-25-002209.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":42,"match_count":4,"context":"ue to an escalation of terrorist or counter terrorist activity; any changes in our business relationships with international distributors or the economic climate they operate in; any event that has a material adverse impact on our foreign manufacturing operations may adversely affect our operations as a whole; failure to manage the future expansion of our business could have a material adverse effect on our revenues and","filed_date":"2021-04-14","accession":"0001513162-21-000056","full_text":"https://origin.rootz.global/static/filing/0001513162-21-000056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":42,"match_count":4,"context":"ue to an escalation of terrorist or counter terrorist activity; any changes in our business relationships with international distributors or the economic climate they operate in; any event that has a material adverse impact on our foreign manufacturing operations may adversely affect our operations as a whole; failure to manage the future expansion of our business could have a material adverse effect on our revenues and","filed_date":"2021-01-14","accession":"0001513162-21-000006","full_text":"https://origin.rootz.global/static/filing/0001513162-21-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":42,"match_count":4,"context":"ue to an escalation of terrorist or counter terrorist activity; any changes in our business relationships with international distributors or the economic climate they operate in; any event that has a material adverse impact on our foreign manufacturing operations may adversely affect our operations as a whole; failure to manage the future expansion of our business could have a material adverse effect on our revenues and","filed_date":"2020-10-15","accession":"0001513162-20-000216","full_text":"https://origin.rootz.global/static/filing/0001513162-20-000216.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_concentration","strength":41,"match_count":2,"context":"nd results of operations. We also have supply agreements with foreign vendors that involve sharing foreign currency exchange fluctuation risks. We may enter into similar arrangements in the future. A significant portion of our revenues comes from sales to our distribution partner in China. Political tensions between the U.S. and China could disrupt or reduce our sales in the Chinese market, posing a substantial risk to our busines","filed_date":"2025-08-29","accession":"0001641172-25-026041","full_text":"https://origin.rootz.global/static/filing/0001641172-25-026041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BMRA","company":"BIOMERICA INC","exchange":"Nasdaq","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"r options held at the fiscal year-end. | | |  |  | | |  (2) |  For Mr. Zackary Irani, 25% of the option awards granted on 12/7/2023 vested immediately, while the remaining 75% will vest in equal installments over a 36-month period. The option awards granted to him on 1/22/2018 also vest in equal installments over a 36-month period. All other option awards granted to Mr. Zackary Irani vest in equal in","filed_date":"2024-09-30","accession":"0001493152-24-038820","full_text":"https://origin.rootz.global/static/filing/0001493152-24-038820.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"84d1c24335c1bc3155628b83268df4e4a2d91d43b17e62f0538b3c332f8aeed4","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"30ce3aa725c3fc64f8222aa17d228c084b206c34c5139b5becfcc4e34243a5ea","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":59,"hourly_limit":500,"remaining":441,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}